16:32 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

AbbVie's elagolix meets in second Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-II (M12-817) trial, the second of two replicate Phase III trials of the non-peptide small molecule...
18:08 , Mar 13, 2018 |  BC Extra  |  Clinical News

AbbVie's elagolix meets in second Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-II (M12-817) trial, the second of two replicate Phase III trials of the candidate to treat...
20:34 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

AbbVie's elagolix meets in Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-I (M12-815) trial to treat uterine fibroids. The trial is the first of two replicate Phase...
20:06 , Feb 21, 2018 |  BC Extra  |  Clinical News

AbbVie's elagolix meets in Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-I (M12-815) trial to treat uterine fibroids. The trial is the first of two replicate Phase...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

Elagolix: Phase III started

AbbVie began double-blind, placebo-controlled, U.S. Phase III trial to evaluate oral elagolix with or without estradiol/norethindrone acetate in about 400 patients. The trial includes a 6-month extension study. Enrollment of the first patient triggered a...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Elagolix: Phase IIb data

The double-blind, international Phase IIb M12-813 trial in about 567 premenopausal women with heavy menstrual bleeding associated with uterine fibroids showed that twice-daily 300 mg and once-daily 600 mg oral elagolix for 24 weeks alone...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

Secnidazole: Phase I data

An open-label Phase I trial in 54 healthy female volunteers showed that co-administration of a single dose of 2 g oral SYM-1219 a single dose of an ethinyl estradiol/norethindrone combination birth control pill on the...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

Noven, Novartis deal

Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530, Tosu, Japan)and Novartis dissolved Vivelle Ventures LLC, a JV formed in 1998 between Novartis and Hisamitsu's Noven Pharmaceuticals Inc. subsidiary. Novartis said the partners mutually decided to dissolve the JV,...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Clinical News

Elagolix: Phase IIb started

Neurocrine began a double-blind, placebo-controlled Phase IIb trial to evaluate elagolix alone and in combination with estradiol/norethindrone acetate therapy for 6 months in about 280 female patients ages 18-49 years with heavy uterine bleeding associated...
07:00 , Oct 15, 2007 |  BioCentury  |  Finance

Ebb & Flow

Profit-taking by investors after its IPO lock-up expired may have been behind last week's share price dip for cancer and autoimmune company Synta (SNTA), which shed $2.24 (20%) to $8.76 despite announcing a potentially blockbuster...